Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...

Dexcom announced a new wave of AI-powered features designed to help users understand how food and daily habits affect their metabolic health.

Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled ...

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the ...

The daily tab highlights a user’s current and recent glucose readings, their time in range, logged events and insights. Insights are displayed at the top of the daily tab. The nutrition section gives ...

Dexcom has won FDA clearance of the Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy. The clearance ...

Dexcom was hit with a consumer class action on Oct. 15 in California Central District Court over alleged defects in its G7 Continuous Glucose Monitoring System. The lawsuit, brought by Cowper Law and ...

Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...

Here are four of the latest recalls and corrections reported to the FDA. Dexcom corrects G7 and One + CGM apps over missed sensor failure alerts: Dexcom is issuing a correction for certain versions of ...

Dexcom, a San Diego biotech company known for its continuous glucose monitoring systems, is laying off a few hundred workers as it moves its operations and manufacturing from California to Arizona.

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...